STAAR Surgical (NASDAQ:STAA) Receives $46.38 Consensus Price Target from Brokerages

Shares of STAAR Surgical (NASDAQ:STAA) have been assigned an average rating of “Hold” from the ten brokerages that are covering the company, Marketbeat.com reports. Six research analysts have rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average 1-year price target among analysts that have issued a report on the stock in the last year is $46.38.

Several equities research analysts have recently weighed in on the company. Piper Sandler reduced their price objective on STAAR Surgical from $40.00 to $33.00 and set a “neutral” rating for the company in a research note on Tuesday, February 27th. Canaccord Genuity Group raised their price objective on shares of STAAR Surgical from $32.00 to $46.00 and gave the stock a “hold” rating in a research note on Monday, April 8th. Needham & Company LLC reiterated a “hold” rating on shares of STAAR Surgical in a report on Thursday, April 4th. Stifel Nicolaus restated a “buy” rating and set a $50.00 price objective on shares of STAAR Surgical in a research report on Monday, April 1st. Finally, Mizuho raised their price target on shares of STAAR Surgical from $45.00 to $53.00 and gave the stock a “buy” rating in a report on Thursday, April 11th.

STAAR Surgical Trading Down 0.1 %

Shares of STAA opened at $45.51 on Wednesday. The stock has a 50 day moving average of $41.08 and a 200-day moving average of $35.86. STAAR Surgical has a 52 week low of $26.66 and a 52 week high of $69.00. The firm has a market cap of $2.24 billion, a price-to-earnings ratio of 105.84 and a beta of 0.80.

STAAR Surgical (NASDAQ:STAA) last issued its earnings results on Monday, February 26th. The medical instruments supplier reported $0.16 EPS for the quarter, missing analysts’ consensus estimates of $0.17 by ($0.01). The company had revenue of $76.27 million during the quarter, compared to analyst estimates of $75.94 million. STAAR Surgical had a net margin of 6.62% and a return on equity of 8.73%. The business’s revenue was up 19.1% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.04 earnings per share. On average, sell-side analysts predict that STAAR Surgical will post 0.03 earnings per share for the current fiscal year.

Insider Transactions at STAAR Surgical

In other STAAR Surgical news, Director Aimee S. Weisner bought 1,750 shares of STAAR Surgical stock in a transaction dated Thursday, March 14th. The shares were acquired at an average cost of $38.11 per share, with a total value of $66,692.50. Following the acquisition, the director now directly owns 10,864 shares of the company’s stock, valued at $414,027.04. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. 1.10% of the stock is owned by insiders.

Institutional Investors Weigh In On STAAR Surgical

Institutional investors and hedge funds have recently made changes to their positions in the company. State of Alaska Department of Revenue boosted its holdings in STAAR Surgical by 403.9% during the third quarter. State of Alaska Department of Revenue now owns 30,197 shares of the medical instruments supplier’s stock worth $1,213,000 after buying an additional 24,204 shares during the last quarter. Maryland State Retirement & Pension System acquired a new position in STAAR Surgical in the 3rd quarter worth $718,000. New York State Teachers Retirement System raised its stake in shares of STAAR Surgical by 3.5% in the 3rd quarter. New York State Teachers Retirement System now owns 58,340 shares of the medical instruments supplier’s stock valued at $2,344,000 after purchasing an additional 1,979 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank lifted its holdings in shares of STAAR Surgical by 17.1% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 8,639 shares of the medical instruments supplier’s stock valued at $347,000 after purchasing an additional 1,259 shares in the last quarter. Finally, Oregon Public Employees Retirement Fund boosted its position in shares of STAAR Surgical by 2.8% during the third quarter. Oregon Public Employees Retirement Fund now owns 14,400 shares of the medical instruments supplier’s stock worth $579,000 after buying an additional 391 shares during the period. Institutional investors own 96.70% of the company’s stock.

STAAR Surgical Company Profile

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia.